NexgenRx Inc. (TSXV:NXG)

Accolade Statistics

Total Valuation

NexgenRx has a market cap or net worth of CAD 26.31 million. The enterprise value is 26.27 million.

Market Cap	26.31M
Enterprise Value	26.27M

Important Dates

The next estimated earnings date is Monday, August 18, 2025.

Earnings Date	Aug 18, 2025
Ex-Dividend Date	Apr 25, 2025

Share Statistics

NexgenRx has 71.12 million shares outstanding. The number of shares has increased by 11.90% in one year.

Current Share Class	71.12M
Shares Outstanding	71.12M
Shares Change (YoY)	+11.90%
Shares Change (QoQ)	-7.84%
Owned by Insiders (%)	37.18%
Owned by Institutions (%)	n/a
Float	44.38M

Valuation Ratios

The trailing PE ratio is 36.88.

PE Ratio	36.88
Forward PE	n/a
PS Ratio	1.54
PB Ratio	3.25
P/TBV Ratio	8.06
P/FCF Ratio	15.00
P/OCF Ratio	12.63
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.47, with an EV/FCF ratio of 14.97.

EV / Earnings	31.37
EV / Sales	1.54
EV / EBITDA	14.47
EV / EBIT	17.26
EV / FCF	14.97

Financial Position

The company has a current ratio of 1.10, with a Debt / Equity ratio of 0.05.

Current Ratio	1.10
Quick Ratio	0.10
Debt / Equity	0.05
Debt / EBITDA	0.24
Debt / FCF	0.25
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 12.52% and return on invested capital (ROIC) is 11.23%.

Return on Equity (ROE)	12.52%
Return on Assets (ROA)	2.87%
Return on Invested Capital (ROIC)	11.23%
Return on Capital Employed (ROCE)	17.95%
Revenue Per Employee	853,973
Profits Per Employee	41,871
Employee Count	20
Asset Turnover	0.52
Inventory Turnover	n/a

Taxes

In the past 12 months, NexgenRx has paid 412,150 in taxes.

Income Tax	412,150
Effective Tax Rate	29.14%

Stock Price Statistics

The stock price has increased by +48.00% in the last 52 weeks. The beta is 0.84, so NexgenRx's price volatility has been lower than the market average.

Beta (5Y)	0.84
52-Week Price Change	+48.00%
50-Day Moving Average	0.33
200-Day Moving Average	0.29
Relative Strength Index (RSI)	63.26
Average Volume (20 Days)	3,930

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NexgenRx had revenue of CAD 17.08 million and earned 837,426 in profits. Earnings per share was 0.01.

Revenue	17.08M
Gross Profit	13.72M
Operating Income	1.52M
Pretax Income	1.41M
Net Income	837,426
EBITDA	1.73M
EBIT	1.52M
Earnings Per Share (EPS)	0.01

Balance Sheet

The company has 2.13 million in cash and 437,177 in debt, giving a net cash position of 1.70 million or 0.02 per share.

Cash & Cash Equivalents	2.13M
Total Debt	437,177
Net Cash	1.70M
Net Cash Per Share	0.02
Equity (Book Value)	8.09M
Book Value Per Share	0.09
Working Capital	2.83M

Cash Flow

In the last 12 months, operating cash flow was 2.08 million and capital expenditures -328,706, giving a free cash flow of 1.75 million.

Operating Cash Flow	2.08M
Capital Expenditures	-328,706
Free Cash Flow	1.75M
FCF Per Share	0.02

Margins

Gross margin is 80.35%, with operating and profit margins of 8.91% and 5.87%.

Gross Margin	80.35%
Operating Margin	8.91%
Pretax Margin	8.28%
Profit Margin	5.87%
EBITDA Margin	10.11%
EBIT Margin	8.91%
FCF Margin	10.27%

Dividends & Yields

This stock pays an annual dividend of 0.01, which amounts to a dividend yield of 2.70%.

Dividend Per Share	0.01
Dividend Yield	2.70%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	90.70%
Buyback Yield	-11.90%
Shareholder Yield	-9.20%
Earnings Yield	3.18%
FCF Yield	6.67%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	7